NEW YORK – Digital diagnostics company EDX Medical said Monday that it signed a mutually exclusive agreement to distribute Caris Life Sciences' solid tumor and liquid biopsy assays, as well as its artificial intelligence tools throughout the UK and four Nordic countries, for at least three years.
Cambridge, UK-based EDX Medical will initially distribute these throughout the UK, Sweden, Denmark, Norway, and Finland, with other regions and products to be included in the future.
Financial details of the agreement were not disclosed.
"The pace of scientific advancement is such that for a patient with cancer who may only be able to provide one sample and urgently needs to start optimal treatment, reviewing their whole exome and transcriptome rather than a smaller selection of genes limited by current knowledge is clearly the most robust clinical approach," Sir Chris Evans, founder of EDX Medical, said in a statement.
Last year, EDX Medical signed a similar deal with Guardant Health to distribute the Guardant360 CDx advanced cancer genomic test and the Guardant Reveal test for residual disease and recurrence detection in early-stage cancer throughout the UK and to distribute Guardant360 CDx to the public and private sectors in Sweden, Denmark, Norway, Finland, and Iceland.
EDX Medical has also been building out its lateral flow assay business with technology gained from Torax Biosciences, which the firm acquired last year.